A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659).

4096Background: PNETs are distinguished by increased vascularity and benefit from anti-angiogenic therapies. PZ is a tyrosine kinase inhibitor(TKI) of VEGFR-1-3, PDGFR-α, -β, and c-Kit with single...